80 results
Page 2 of 4
8-K
EX-99.1
q2y1hrd jkmfoh8mr8nz
8 Aug 22
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
4:32pm
8-K
EX-99.1
wg9jno5kq
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
b57dqk49
27 Jun 22
Entry into a Material Definitive Agreement
7:31pm
8-K
EX-99.1
ap3q33j9k494 ff5w
16 Jun 22
Other Events
7:00am
8-K
EX-99.1
ywtwigf4
9 May 22
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
4:31pm
POS AM
pge 00mgkotp
28 Feb 22
Prospectus update (post-effective amendment)
5:46pm
8-K
EX-99.1
qfnto8uda3w4uu
28 Feb 22
Sutro Biopharma Reports Full Year 2021 Financial Results, Business Highlights, and Anticipated 2022 Milestones
4:36pm
POSASR
trottlrjjxf0dyw v46
28 Feb 22
Automatic shelf registration (post-effective amendment)
4:16pm
8-K
EX-99.1
yj1 asbqei58sge
10 Jan 22
Regulation FD Disclosure
7:01am
8-K
EX-99.1
6to57
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
0ibc gnofnf8781sy
10 Nov 21
Sutro Biopharma Reports Third Quarter 2021 Financial Results, Business Highlights, and Anticipated 2021 Milestones
7:03am
8-K
EX-99.1
3weuadtskd7g3zzq
9 Aug 21
Business Highlights and Anticipated Second Half 2021 Milestones
7:01am